Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    Levo-tetrahydropalmatine (l-THP) molecular structure

    Levo-tetrahydropalmatine (l-THP)

    NootropicsApproved (China)

    Also known as: l-THP, Rotundine, (-)-Tetrahydropalmatine, Gindarine, Hyndarine, Caseanine, Jin Bu Huan (herbal product containing l-THP)

    Levo-tetrahydropalmatine, usually written l-THP, is an isoquinoline alkaloid found in plants of the Corydalis and Stephania genera. It is not a new compound.

    Disguised Alpha logo

    Lowest price

    $59.9960 capsules

    at Disguised Alpha

    Half-life: Not established in the sources retrievedRoute: OralMW: 355.43 g/molCAS: 483-14-7
    Last reviewed:

    Overview

    At A Glance

    Mechanism

    l-THP is a non-selective dopamine receptor antagonist. Radioligand and behavioral work in rats identified higher-affinity antagonism at D1 receptors, lower-affinity antagonism at D2 receptors and interaction with D3 receptors (PMID: 17361394), and reviews add activity at alpha ad…

    Half-Life
    Not established in the sources retrieved; a randomized, double-blind, placebo-controlled human study collected full plasma pharmacokinetic profiles in 19 cocaine users receiving l-THP 30 mg twice daily for 4 days but did not report a terminal half-life (PMID: 27363313)
    Routes
    Oral
    Potential Benefits
    Reduced cocaine self-administration and cocaine-induced reinstatement in rats at doses that did not change food-reinforced responding (PMID: 17361394)Reduced reinstatement of extinguished cocaine seeking triggered by cocaine, stress or drug-associated cues in rats after oral administration (PMID: 21196089)Reduced nicotine self-administration and reinstatement in rats (PMID: 27817750)Reduced voluntary ethanol drinking in C57BL/6J mice in a two-bottle choice test (PMID: 23376703)Safe and well tolerated over a short course in 24 adult male cocaine users, without changing cocaine pharmacokinetics or its acute cardiovascular effects (PMID: 27363313)

    Overview

    Levo-tetrahydropalmatine, usually written l-THP, is an isoquinoline alkaloid found in plants of the Corydalis and Stephania genera. It is not a new compound. It has been approved and used in China for decades under the drug name Rotundine for several clinical indications, mainly as an analgesic with sedative and hypnotic effects (PMID: 22300097, PMID: 27606501). Outside China it is known in two very different contexts: as a candidate treatment for cocaine and opioid addiction, and as the active constituent of the herbal product Jin Bu Huan that caused a cluster of poisonings in the United States during the 1990s. Its pharmacology is dopamine receptor antagonism. Radioligand and behavioral work in rats found higher-affinity antagonism at D1 receptors, lower-affinity antagonism at D2 receptors and interaction with D3 receptors, and reviews add activity at alpha adrenergic and serotonin receptors (PMID: 17361394, PMID: 22300097). In C57BL/6J mice, treatment reduced voluntary ethanol drinking and altered D2 receptor-linked protein kinase A signaling in the caudate-putamen but not the nucleus accumbens (PMID: 23376703). The animal addiction work is consistent. In rats, l-THP shifted the cocaine self-administration dose-response curve down and to the right and reduced cocaine-induced reinstatement at doses that did not change food-reinforced responding (PMID: 17361394); reduced reinstatement triggered by cocaine, stress or drug-associated cues after oral administration (PMID: 21196089); reduced cocaine self-administration under a progressive ratio schedule (PMID: 20816889); and reduced nicotine self-administration and reinstatement (PMID: 27817750). Human work is real but small. A randomized, double-blind, placebo-controlled study gave 24 adult male cocaine users l-THP 30 mg twice daily or placebo for four days, with an intranasal cocaine challenge on the fourth day. The short course was safe and well tolerated, side effect counts matched placebo, and l-THP did not change cocaine exposure or its acute cardiovascular effects (PMID: 27363313). Registered work at the University of Maryland includes that Phase 1 study (NCT01631383), a completed 63-participant study in schizophrenia (NCT02118610) and a Phase 2 cocaine use disorder trial that was withdrawn before enrolment (NCT02139761). No adequately powered efficacy trial has been published. The safety record deserves weight. Jin Bu Huan Anodyne tablets, which contain l-THP and were mislabelled on the package as a Lycopodium product, caused acute hepatitis in seven previously healthy adults after a mean of 20 weeks of use, with recurrence on rechallenge in two of them (PMID: 7944049). A separate case series described life-threatening neurological and cardiovascular effects including coma in three young children after single acute ingestions, alongside hepatitis in three adults on long-term use (PMID: 8774209), and chronic hepatitis with moderate fibrosis has been reported after two months of use (PMID: 9537855). In human liver microsomes, tetrahydropalmatine is a mechanism-based inhibitor of CYP2D6 and is itself metabolized by CYP2C19, CYP3A4, CYP1A2 and CYP2D6, which makes interaction with CYP2D6 substrates a live concern (PMID: 41876357). l-THP has no FDA or EMA authorization. Capsules sold on the research chemical and supplement market are not the Chinese pharmaceutical product and are not made to a pharmacopoeial standard.

    Potential Research Fields

    Addiction pharmacotherapyDopamine receptor antagonistsHerbal medicine safetyAnalgesia and sedation

    Chemical Information

    IUPAC Name

    Not yet available

    CAS Number

    483-14-7

    Molecular Formula

    C21H25NO4

    Molecular Mass

    355.43 g/mol

    Dosing & Protocols

    Unlock the Dosing tab

    Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

    • Route

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    Research

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    Interactions

    Contraindications

    Sourced: liver disease or concurrent hepatotoxic exposure, given documented hepatitis after prolonged use of l-THP-containing herbal products (PMID: 7944049, PMID: 9537855), and children, given reported coma and cardiovascular collapse after single ingestions in three young children (PMID: 8774209). Mechanism-based: tetrahydropalmatine is a mechanism-based CYP2D6 inhibitor in human liver microsomes, so drugs cleared by CYP2D6 are an interaction concern (PMID: 41876357), and dopamine receptor antagonism is a mechanism-based concern for anyone taking dopaminergic or antipsychotic medication (PMID: 17361394).

    Research Disclaimer

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Best Price

    $59.99

    Best $/mg

    —

    Vendors

    1

    Listings

    1

    capsule

    Form
    Sort
    Vendor Product Form Qty Price $/mg Coupon
    Disguised Alpha logo
    Disguised Alpha
    50
    🇺🇸US🇪🇺EU🇬🇧UK
    L-THP capsules (60) capsule 60 capsules● In Stock $59.99BEST — —

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Levo-tetrahydropalmatine (l-THP).

    Current low
    $59.99
    current listings
    7-day low
    —
    not enough history yet
    30-day low
    —
    not enough history yet
    30-day change
    —
    not enough history yet

    Tracking since Sep 7, 2026 · 1 data point

    Vendors Selling Levo-tetrahydropalmatine (l-THP)

    How we score these vendors

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.

    View Scorecard

    Related Compounds

    View All

    9-Me-BC (9-Methyl-β-carboline)

    NootropicsPreclinical

    9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].

    t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists.
    6 PubMedView Profile

    Aniracetam

    NootropicsApproved (Italy)

    Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.

    t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
    PreclinicalView Profile

    Bemethyl (bemitil)

    NootropicsApproved (Russia)

    Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.

    t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773)
    PreclinicalView Profile

    Bromantane

    NootropicsRussia Approved

    Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.

    34 PubMedView Profile

    Cyclazodone

    NootropicsPreclinical

    Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.

    PreclinicalView Profile

    Dihexa

    NootropicsPreclinical

    Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.

    t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose)
    1 PubMedView Profile

    View Full Dosage Guide →

    Protocols, calculator & safety for Levo-tetrahydropalmatine (l-THP)

    Lowest Price

    Disguised Alpha logo

    Disguised Alpha

    $59.99

    1 vendor · 1 listing

    Research Score

    30

    0 PubMed results

    Quality Indicators

    Data Completeness

    63%
    Description
    Mechanism of Action
    Chemical Data
    Dosing Protocols
    Safety Profile
    PubMed Results
    Interactions
    Vendor Listings

    COA Verification

    0

    Verified COAs

    1

    Vendors w/ COA

    Latest test: 9/16/2026

    Quick Facts

    Half-Life

    Not established in the sources retrieved; a randomized, double-blind, placebo-controlled human study collected full plasma pharmacokinetic profiles in 19 cocaine users receiving l-THP 30 mg twice daily for 4 days but did not report a terminal half-life (PMID: 27363313)

    Molecular Weight

    355.43 g/mol

    Administration

    Oral

    CAS Number

    483-14-7

    Trial Phase

    Approved (China)

    Research Disclaimer

    This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

    Frequently Asked Questions

    What is Levo-tetrahydropalmatine (l-THP) used for in research?

    Levo-tetrahydropalmatine, usually written l-THP, is an isoquinoline alkaloid found in plants of the Corydalis and Stephania genera. It is not a new compound. It has been approved and used in China for decades under the drug name Rotundine for several clinical indications, mainly as an analgesic with sedative and hypnotic effects (PMID: 22300097, PMID: 27606501). Outside China it is known in two very different contexts: as a candidate treatment for cocaine and opioid addiction, and as the active constituent of the herbal product Jin Bu Huan that caused a cluster of poisonings in the United States during the 1990s.

    Its pharmacology is dopamine receptor antagonism. Radioligand and behavioral work in rats found higher-affinity antagonism at D1 receptors, lower-affinity antagonism at D2 receptors and interaction with D3 receptors, and reviews add activity at alpha adrenergic and serotonin receptors (PMID: 17361394, PMID: 22300097). In C57BL/6J mice, treatment reduced voluntary ethanol drinking and altered D2 receptor-linked protein kinase A signaling in the caudate-putamen but not the nucleus accumbens (PMID: 23376703).

    The animal addiction work is consistent. In rats, l-THP shifted the cocaine self-administration dose-response curve down and to the right and reduced cocaine-induced reinstatement at doses that did not change food-reinforced responding (PMID: 17361394); reduced reinstatement triggered by cocaine, stress or drug-associated cues after oral administration (PMID: 21196089); reduced cocaine self-administration under a progressive ratio schedule (PMID: 20816889); and reduced nicotine self-administration and reinstatement (PMID: 27817750).

    Human work is real but small. A randomized, double-blind, placebo-controlled study gave 24 adult male cocaine users l-THP 30 mg twice daily or placebo for four days, with an intranasal cocaine challenge on the fourth day. The short course was safe and well tolerated, side effect counts matched placebo, and l-THP did not change cocaine exposure or its acute cardiovascular effects (PMID: 27363313). Registered work at the University of Maryland includes that Phase 1 study (NCT01631383), a completed 63-participant study in schizophrenia (NCT02118610) and a Phase 2 cocaine use disorder trial that was withdrawn before enrolment (NCT02139761). No adequately powered efficacy trial has been published.

    The safety record deserves weight. Jin Bu Huan Anodyne tablets, which contain l-THP and were mislabelled on the package as a Lycopodium product, caused acute hepatitis in seven previously healthy adults after a mean of 20 weeks of use, with recurrence on rechallenge in two of them (PMID: 7944049). A separate case series described life-threatening neurological and cardiovascular effects including coma in three young children after single acute ingestions, alongside hepatitis in three adults on long-term use (PMID: 8774209), and chronic hepatitis with moderate fibrosis has been reported after two months of use (PMID: 9537855). In human liver microsomes, tetrahydropalmatine is a mechanism-based inhibitor of CYP2D6 and is itself metabolized by CYP2C19, CYP3A4, CYP1A2 and CYP2D6, which makes interaction with CYP2D6 substrates a live concern (PMID: 41876357).

    l-THP has no FDA or EMA authorization. Capsules sold on the research chemical and supplement market are not the Chinese pharmaceutical product and are not made to a pharmacopoeial standard.

    What forms does Levo-tetrahydropalmatine (l-THP) come in?

    Levo-tetrahydropalmatine (l-THP) is available in capsule form.

    How do I compare Levo-tetrahydropalmatine (l-THP) vendors?

    Compare prices, payment methods, shipping, and COA scores across 1 vendor.

    How many vendors sell Levo-tetrahydropalmatine (l-THP), and what does it cost per mg?

    1 of the vendors BodyHackGuide tracks list Levo-tetrahydropalmatine (l-THP) (1 listing). The lowest listed price BodyHackGuide has recorded for Levo-tetrahydropalmatine (l-THP) is $59.99. No Levo-tetrahydropalmatine (l-THP) listing recorded as in stock carries a milligram count, so BodyHackGuide states no price per milligram for Levo-tetrahydropalmatine (l-THP).

    Which vendors have third-party COAs for Levo-tetrahydropalmatine (l-THP) on file at BodyHackGuide?

    BodyHackGuide holds 1 third-party certificate record for Levo-tetrahydropalmatine (l-THP), from Disguised Alpha. No editor has read any of BodyHackGuide's 1 certificate record for Levo-tetrahydropalmatine (l-THP). The laboratory named on BodyHackGuide's Levo-tetrahydropalmatine (l-THP) certificate record is Freedom Diagnostics Testing, and the test date on it is 30 July 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Research Tools

    You may also like

    Related Compounds

    View All

    9-Me-BC (9-Methyl-β-carboline)

    NootropicsPreclinical

    9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].

    t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists.
    6 PubMedView Profile

    Aniracetam

    NootropicsApproved (Italy)

    Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.

    t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
    PreclinicalView Profile

    Bemethyl (bemitil)

    NootropicsApproved (Russia)

    Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.

    t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773)
    PreclinicalView Profile

    Bromantane

    NootropicsRussia Approved

    Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.

    34 PubMedView Profile

    Cyclazodone

    NootropicsPreclinical

    Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.

    PreclinicalView Profile

    Dihexa

    NootropicsPreclinical

    Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.

    t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose)
    1 PubMedView Profile

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.